A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Neratinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2017 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.
- 07 Sep 2017 Planned primary completion date changed from 1 Aug 2025 to 1 Dec 2025.
- 07 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Dec 2017.